NCT06276088View on ClinicalTrials.gov

Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy

RecruitingOBSERVATIONAL
Enrollment

374

Participants

Timeline

Start Date

February 18, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

October 31, 2026

Conditions
ImmunotherapyHyperprogressionBiomarker
Trial Locations (5)

510515

RECRUITING

Nanfang hospital, Southern medical university, Guangzhou

Unknown

NOT_YET_RECRUITING

Fujian Provinical Hospital, Fuzhou

NOT_YET_RECRUITING

Huizhou Central People's Hospital, Huizhou

NOT_YET_RECRUITING

Jieyang people's hospital, Jieyang

NOT_YET_RECRUITING

Meizhou People's Hospital, Meizhou Academy of Medical Sciences Meizhou, Meizhou

All Listed Sponsors
lead

Nanfang Hospital, Southern Medical University

OTHER